Maximus (MMS) Q3 2026 Earnings Call Transcript
Maximus (MMS) reported Q3 FY2026 revenue of $1.28B and adjusted diluted EPS of $2.22. Adjusted EBITDA margin rose to 15.0%. The company reiterated FY2026 revenue guidance of $5.2B to $5.35B but lowered adjusted EPS to $7.90 to $8.20 due to a temporary suspension of VA MDE performance incentives. Free cash flow guidance was revised to $425M to $475M.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the combination of (1) reiterated FY26 revenue range, (2) lowered FY26 adjusted EPS guidance due to VA MDE performance-incentive suspension through Dec. 31, 2026, and (3) revised FY26 free cash flow guidance amid DSO/collections timing.
Market read
Guidance adjustments tied to a specific federal program pause and working-capital timing create a clear near-term earnings and cash-flow narrative for MMS positioning.
What to watch
Book-to-bill is ~0.5x and awarded-but-unsigned contracts are $1.35B, so investors may scrutinize whether pipeline conversion delays could offset margin improvements and the stated return to organic growth in Q4.
Background
This is a transcript-style summary of Maximus’ Fiscal 2026 Q3 earnings call, including segment performance, working capital, and updated full-year guidance.
Ticker impact
Maximus reported Q3 revenue of $1.28B and reiterated FY26 revenue guidance while lowering FY26 adjusted EPS to $7.90-$8.20.
Near-term bias depends on how investors weigh the EPS guide cut and FCF outflow versus the reiterated revenue range and improving operating margins.
The article discloses multiple decision-relevant datapoints: EPS guidance reduction ($0.35 impact), FCF guidance revision ($425M-$475M), DSO/collections update ($245M collected in July), and an expected incentive pause through Dec. 31, 2026.
Market effects
Highlights ongoing execution and margin levers in U.S. federal outsourcing and program-integrity/benefits administration work.
Primarily U.S.-federal and state Medicaid/SNAP implementation dynamics.
Limited, with outside the U.S. revenue described as $140M and focused on pipeline conversion rather than major international catalysts.
Counterpoint
The EPS guide cut is explicitly linked to a temporary incentive suspension; if the VA MDE rebid scope and collections normalize, the market may over-discount the earnings impact.
Key entities
- companyMaximus, Inc.
U.S. federal services and benefits administration contractor reporting Q3 results and updating FY26 guidance.
- programDepartment of Veterans Affairs Medical Disability Exam (VA MDE) program
VA program whose performance incentives are temporarily suspended effective July 1, 2026, impacting FY26 EPS.
- programSNAP
Supplemental Nutrition Assistance Program, with a stated increase in state administrative cost share beginning Oct. 1, 2026.
- legislationH.R. 1
Working Families Tax Cut Act referenced for Medicaid and SNAP requirement implementation driving U.S. Services growth expectations.
